Optimal Bayesian-feasible dose escalation for cancer phase I trials
We present an adaptive dose escalation scheme for cancer phase I clinical trials which is based on a parametric quantal response model. The dose escalation is Bayesian-feasible, Bayesian-optimal and consistent. It is designed to approach the maximum tolerated dose as fast as possible subject to the constraint that the predicted probability of assigning doses higher than the maximum tolerated dose is equal to a specified value.
Year of publication: |
1998
|
---|---|
Authors: | Zacks, S. ; Rogatko, A. ; Babb, J. |
Published in: |
Statistics & Probability Letters. - Elsevier, ISSN 0167-7152. - Vol. 38.1998, 3, p. 215-220
|
Publisher: |
Elsevier |
Keywords: | Dose escalation scheme Cancer phase I clinical trials Bayesian adaptive procedure Constrained optimization Bayesian feasible scheme Consistent escalation scheme |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Estimating the shift to wear-out of systems having exponential-Weibull life distributions
Zacks, S., (1984)
-
Bayes procedures for detecting a shift in the probability of success in a series of Bernoulli trials
Zacks, S., (1981)
-
Problems and approaches in design of experiments for estimation and testing in non-linear models
Zacks, S., (1977)
- More ...